Novartis Pauses Study of GenVec's Gene Therapy CFG166 (UPDATE May 2016: Trial Is Again Continuing)

Discussion in 'Research News' started by Yahzib Rafiq, Jan 12, 2016.

    1. Margus

      Margus Member

      Tinnitus Since:
      01/2015
      Cause of Tinnitus:
      Unknown
      Any news on CFG-166? Estimated trial completion date was December 5th.
       
      • Like Like x 2
      • Good Question Good Question x 1
    2. Hammers

      Hammers Member

      Tinnitus Since:
      04/19
      Cause of Tinnitus:
      Acoustic Trauma: Too close to fireworks with no protection.
      Still nothing on their website or the ClinicalTrials.gov page...
       
    3. mrbrightside614

      mrbrightside614 Member Podcast Patron Benefactor Advocate

      Location:
      NE Ohio, USA
      Tinnitus Since:
      July 2019
      Cause of Tinnitus:
      Acoustic trauma
      Probably takes some time to officially report results, but this therapy was not at all on my radar so it’s nice to see that there’s another player in this game that (may be) close to reaching the market.
       
    4. Coleoptere
      Alone

      Coleoptere Member

      Location:
      The Hague
      Tinnitus Since:
      2002
      Cause of Tinnitus:
      Bell's Palsy, hearing loss
      Not so good news. This trail is suspended again:

      https://www.hearinglossjournal.com/novartis-suspends-cgf166-trials/

      Remember: CGF166 is delivered by a small surgical operation where the eardrum is temporarly shifted aside. Not a very attractive treatment but it is intended for people with profound hearing loss. Again little is known about the exact results achieved until now.
       
      • Informative Informative x 1
    5. FGG
      No Mood

      FGG Member Podcast Patron Benefactor Hall of Fame Advocate

      Tinnitus Since:
      01/2019
      Cause of Tinnitus:
      Multi-factorial
      A few of my thoughts of the problems with this:

      This procedure uses a cochleostomy to insert the medication, which causes enough inflammation to be very destructive to hair cells, sometimes widely.

      There is a newer surgical method for delivery of AAV involving a canalostomy. This procedure is completely safe for the cochlea. It would be great if they could switch over to this method.

      Very severe to profound loss means you have little to no support cells left, which means there is no substrate for the drug to act on. The ones who benefited likely had less severe audiograms.

      I am willing to bet when they restart they will cap the thresholds around 70dB-80dB losses.
       
      • Agree Agree x 1

Share This Page

Loading...
Similar Threads - Novartis Pauses Study
  1. WaqasVic
    Replies:
    2
    Views:
    428